Elevated Suicide Risk Identified in People with Headache Disorders
Post-traumatic headaches and trigeminal autonomic cephalalgia significantly increased the risk for attempted and completed suicide, according to new study.
Use of Perioperative Multimodal Pain Management in the US Remains Low, Expert Says
An anesthesiologist and renowned investigator in use of nonopioids as part of multimodal pain management, Edward Mariano, MD, MAS, describes slow uptake in the field.
Vistagen Wins US Patent for Investigational NMDA Receptor Antagonist to Treat Neuropathic Pain
AV-101 is an orally bioavailable small molecule NMDA receptor antagonist with antinociceptive effects similar to gabapentin but with more a more favorable safety profile.
FDA Approves Nonopioid Journavx for Acute Pain: Daily Dose
Your daily dose of the clinical news you may have missed.
FDA Approves AbbVie's Combination Antibiotic Emblaveo for Complicated Intra-Abdominal Infections
The novel therapy combines aztreonam, a monobactam antibiotic, and avibactam, a β-lactamase inhibitor.
Atopic Dermatitis First, Now Onto Asthma for Enveda's Oral Small Molecule Anti-inflammatory Candidate
The investigational molecule with “JAK-inhibitor-like efficacy and IL4/IL13-like safety,” was cleared in Q4 2024 by the FDA for an IND application, the company said.
Nasal COVID-19 Vaccine Poised to Enter Phase 1 US Clinical Trial
The study will assess the safety and efficacy of a next-generation COVID-19 vaccine via nasal spray and inhalation.
FDA Grants Priority Review to Brensocatib, First Targeted Treatment for Bronchiectasis
The FDA has set the Prescription Drug User Fee Act target action date for bronchiectasis for August 12, 2025, Insmed Incorporated announced.
US Dementia Cases to Double by 2060: Daily Dose
Hims & Hers Super Bowl Ad for Semaglutide "Nothing Short of Reckless," Says Partnership for Safe Medicines
In letters to the FDA and Fox Broadcasting, PSM enumerated the laws abrogated and the potential harms of the ad being viewed by 200 million people on February 9, 2025.
FDA Approves New Wearable Treatment for Parkinson Disease
Onapgo is the first and only subcutaneous apomorphine infusion device for the treatment of motor fluctuations in people with advanced Parkinson disease.
Opioid Prescribing Has Come a Long Way, According to Stanford Pain Expert Edward Mariano, MD, MAS
Opioid prescribing has seen its extremes, from the 5th Vital Sign era in the aughts to the CDC restrictions of 2016. Mariano talks about the environment right now.
Diabetes Caution: FDA Warns of Risk of Missing Critical Alerts from Smartphone-Compatible Diabetes Devices
Hardware or software changes as well as user adjustments may disable or mute alerts for elevated glycemia, medication use, and other diabetes management essentials, the agency said.
New Study Links Major Depressive Disorder to Specific Changes in Eating Preferences
People with MDD demonstrated a preference for carbohydrate-rich foods and reduced reward from fat- and protein-rich foods, according to new research.
Viking Therapeutics Advances 3 Potential Obesity Treatments Based on Promising 2024 Clinical Trial Results
A GLP-1/GIP dual agonist in both subcutaneous and oral tablet formulations and a novel dual amylin and calcitonin receptor agonist lead the company's pipeline for antiobesity medications.
FDA Greenlights Symbravo for Acute Treatment of Migraine: Daily Dose
Premature Menopause May Increase Risk of Type 2 Diabetes Suggests Study of 1.1 Million Women
Premature menopause, authors said, should be included in diabetes management guidelines as a risk factor to support screening and prevention.
Investigators Identify Hemoglobin A1c/HDL-C as a Predictor of Stroke Risk in Older Adults
Elevated HbA1c/HDL-C ratios significantly increased stroke risk, even after adjusting for confounding factors, reported authors of a recent study.
Roche Receives FDA 510(k) Clearance for First US Blood Test Measuring Lp(a) in Molar Units
The Tina-quant® Lipoprotein (a) Gen.2 Molarity assay measures Lp(a) in molar units, providing a more accurate particle-based risk assessment than mass units.
Study Identifies Key Symptoms of Topical Steroid Withdrawal: Daily Dose
